AUSTIN (June 11, 2007) In keeping with its recent trend of rapid growth, HC&B Healthcare Communications has been awarded two new accounts: Encysive Pharmaceuticals and Exagen Diagnostics, Inc. HC&B has been hired to take Encysive Pharmaceutical's new drug for pulmonary arterial hypertension to market pending its FDA approval. eXagen Diagnostics™, a leader in genomic marker tests for the diagnosis and prognosis of various disease states, will tap the agency for corporate and product branding.

"We are excited about these new accounts, as they reflect our growing experience and expertise in the healthcare communications industry," said Kerry Hilton, President of HC&B.